UCB Pharma is a subsidiary of UCB SA. By November 2005, UCB Pharma employed over 3000 people worldwide and conducted research in the fields of central nervous system (CNS) disorders, including epilepsy, cardiovascular diseases and immunoallergology. It also had a biotechnology company, UCB-Bioproducts, which researched peptides and peptidomimetics with potential therapeutic utility.In January 2000, UCB Pharma acquired the pharmaceutical division of Fujirebio.In October 1999, UCB was involved in the formation of a new company based in France, Genfit SA, which was to provide a technology platform in the area of functional genomics